Infliximab
VIDEO: Recent advancements in rheumatoid arthritis
In this video, Maria Danila, MD, discusses recent advancements in rheumatoid arthritis.
Low anti-TNF concentrations at week 14 linked to long-term loss of response in Crohn’s
Approximately two-thirds of patients with Crohn’s disease who initially responded to anti-tumor necrosis factor therapy lost response by 3 years, with researchers suggesting that higher drug concentrations at induction may improve outcomes.
Second anti-TNF ‘reasonable option’ for UC, whether infliximab or subcutaneous agent
Use of a second anti-tumor necrosis factor agent resulted in early clinical response in nearly 50% of patients with ulcerative colitis and long-term remission in about 30%, with no difference reported between IV and subcutaneous agents.
Infliximab levels above 6.9 mg/L at week 14 predict sustained remission in pediatric IBD
Infliximab concentrations above 6.9 mg/L at 14 weeks after initiation of treatment predicted sustained remission between 26 and 52 weeks in children with inflammatory bowel disease, according to researchers in the Netherlands.
Conversion initiative gives ‘significant’ boost to Remicade biosimilar use
An initiative to switch clinically stable patients from Remicade to a biosimilar significantly increased biosimilar use in rheumatology and gastroenterology clinics within the University of North Carolina health system, according to data.
Q&A: Zymfentra ‘gives patients an option’ for at-home maintenance therapy of IBD
The FDA’s approval of Zymfentra in fall 2023 offers patients the “flexibility” of a subcutaneous therapy option for moderately to severely active ulcerative colitis and Crohn’s disease, Stephen B. Hanauer, MD, told Healio in an interview.
Therapy choice in rheumatoid arthritis does not impact serious infection risk
Among patients with rheumatoid arthritis, the chosen course of therapy does not have an impact on the risk for developing a serious infection, according to data published in Rheumatology.
Medicare fails to ‘keep up with’ Medicaid, private market on infliximab biosimilar uptake
SAN DIEGO — Compared with Medicaid and private insurance, Medicare has lagged significantly in adopting infliximab biosimilars despite the multiple options now available, according to data presented at ACR Convergence 2023.
FDA grants de novo status to ‘5-minute’ drug monitoring tests for Humira, Remicade in IBD
The FDA has granted de novo clearance to ProciseDx Inc. for its therapeutic drug monitoring tests for Humira and Remicade, as well as their biosimilars, in patients with inflammatory bowel disease, according to a company release.
Infliximab may improve visual acuity in PVR associated with RRD
SEATTLE — Patients with proliferative vitreoretinopathy experienced improved visual acuity after receiving an intravitreal injection of infliximab after pars plana vitrectomy, according to a study.